Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?

The stock has climbed in the triple digits over the past three years.Eli Lilly (LLY 1.28%) has already scored major accomplishments in the GLP-1 boom. The company has delivered double-digit revenue growth, taken leadership in the market, and seen its stock price explode higher. GLP-1 drugs have been in great demand as they've helped people quickly and safely shed pounds.Now, though, after Lilly stock's 200% increase over three years, you may be wondering if the growth story has fully played out or if there' ...